NCT03905694 - A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2019

Primary Completion Date

June 29, 2020

Study Completion Date

July 26, 2024

Conditions

Primary HyperoxaluriaPrimary Hyperoxaluria Type 1 (PH1)

Interventions

DRUG

Lumasiran

Lumasiran will be administered by subcutaneous (SC) injection.

Trial Locations (9)

Clinical Trial Site, Rochester

Clinical Trial Site, Houston

Clinical Trial Site, Lyon

Clinical Trial Site, Paris

Clinical Trial Site, Bonn

Clinical Trial Site, Haifa

Clinical Trial Site, Jerusalem

Clinical Trial Site, Nahariya

Clinical Trial Site, London